Castle Biosciences Inc. (CSTL), a molecular diagnostics company focused on dermatologic and gastrointestinal conditions, is drawing attention as it navigates a transitional period marked by modest revenue contraction, a narrowed quarterly loss, and a raised full-year outlook. With a new dermatology test entering the market and a strong cash position, the company is positioning itself for continued operational momentum into 2026.
Stock Performance
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com